Tae Wook Kang

Tae Wook Kang

Auto-generated profile, based on publicly available information

Tae Wook Kang

Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
SLSunyoung Lee
Sunyoung Lee
TKTae Wook Kang
Tae Wook Kang
DCDong Ik Cha
Dong Ik Cha
KSKyoung Doo Song
Kyoung Doo Song
MLMin Woo Lee
Min Woo Lee
KKKyunga Kim
Kyunga Kim

2 September 2019 in European Radiology
Verified
Journal Article
Closed access
PDF file
JLJeong Hyun Lee
Jeong Hyun Lee
IJIjin Joo
Ijin Joo
TKTae Wook Kang
Tae Wook Kang
YPYong Han Paik
Yong Han Paik
DSDong Hyun Sinn
Dong Hyun Sinn
WBWon-Chul Bang
Won-Chul Bang

24 July 2018 in European Radiology
Verified
Journal Article
Closed access
PDF file
RKRan Kim
Ran Kim
TKTae Wook Kang
Tae Wook Kang
DCDong Ik Cha
Dong Ik Cha
KSKyoung Doo Song
Kyoung Doo Song
MLMin Woo Lee
Min Woo Lee
DSDong Hyun Sinn
Dong Hyun Sinn

25 March 2017 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
TKTae Wook Kang
Tae Wook Kang
HLHyo Keun Lim
Hyo Keun Lim
DCDong Ik Cha
Dong Ik Cha
Image-guided radiofrequency ablation (RFA) is an evolving and growing treatment option for patients with hepatocellular carcinoma (HCC) and hepatic metastasis. RFA offers significant advantages as it is less invasive than surgery and carries a low risk of major complications. However, serious complications, including aggressive tumor recurrence, may be observed during follow-up, and recently, mechanical or thermal damage during RFA has been proposed to be one of the causes of this kind of recurrence. Although the exact mechanism of this still remains unclear, physicians should be familiar with the imaging features of aggressive tumor recurrence after RFA for HCC and its risk factors. In addition, in order to prevent or minimize this newly recognized tumor recurrence, a modified RFA technique, combined RFA treatments with transarterial chemoembolization, and cryoablation can be used as alternative treatments. Ultimately, combining an understanding of this potential complication of RFA with an understanding of the possible risk factors for aggressive tumor recurrence and choosing alternative treatments are crucial to optimize clinical outcomes in each patient with HCC.

21 December 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HKHyun A Kim
Hyun A Kim
KKKyung Ah Kim
Kyung Ah Kim
JCJOON-IL CHOI
JOON-IL CHOI
SLSang Min Lee
Sang Min Lee
CLChang Hee Lee
Chang Hee Lee
MCMoon-hyung Choi
Moon-hyung Choi
Ultrasonography (US) is recommended as a standard surveillance tool for patients with a high risk of developing hepatocellular carcinoma (HCC). However, the low sensitivity of US for small HCC can lead to surveillance failure, resulting in advanced stage tumor presentations. For the early detection of HCC in high-risk patients and to improve survival and prognosis, a new efficient imaging tool with a high sensitivity for HCC detection is needed. The purpose of this study is to evaluate and compare the feasibility and efficacy of non-contrast magnetic resonance imaging (MRI) with US as a surveillance tool for HCC in patients with liver cirrhosis. MAGNUS-HCC is a prospective, multicenter clinical trial with a crossover design for a single arm of patients. This study was approved by six Institutional Review Boards, and informed consent was obtained from all participants. All patients will undergo liver US every 6 months and non-contrast liver MRI every 12 months during a follow-up period of 3 years. If a focal liver lesion suspected of harboring HCC is detected, dynamic liver computed tomography (CT) will be performed to confirm the diagnosis. After the last surveillance round, patients without suspicion of HCC or who are not diagnosed with HCC will be evaluated with a dynamic liver CT to exclude false-negative findings. The primary endpoint is to compare the rate of detection of HCC by US examinations performed at 6-month intervals with that of yearly non-contrast liver MRI studies during a 3-year follow-up. The secondary endpoint is the survival of the patients who developed HCC within the 3-year follow-up period. MAGNUS-HCC is the first study to compare the feasibility of non-contrast MRI with US as a surveillance tool for the detection of HCC in high-risk patients. We anticipate that the evidence presented in this study will establish the efficacy of non-contrast MRI as a surveillance tool for HCC in high-risk patients. The date of trial registration ( NCT02551250 ) in this study was September 15, 2015, and follow-up is still ongoing.

1 January 2020 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
JOJoo Hyun Oh
Joo Hyun Oh
DSDong Hyun Sinn
Dong Hyun Sinn
GCGyu-Seong Choi
Gyu-Seong Choi
JKJong Man Kim
Jong Man Kim
JJJae-Won Joh
Jae-Won Joh
MCMoon Seok Choi
Moon Seok Choi
Oh JH, et al. Ann Surg Treat Res. 2020 Oct;99(4):238-246. https://doi.org/10.4174/astr.2020.99.4.238